Announcements Trials
Browse Landscape

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Neuromyelitis Optica 1Myasthenia Gravis 1Hemoglobinuria, Paroxysmal 1Atypical Hemolytic Uremic Syndrome 1

Interventions

Rivaroxaban 8Surveys and Questionnaires 7Heparin, Low-Molecular-Weight 5apixaban 4fludarabine 3Blood Specimen Collection 3pegfilgrastim 2epoetin beta 2Therapeutics 2Polymerase Chain Reaction 2Piperacillin, Tazobactam Drug Combination 2Observation 2Microarray Analysis 2Melphalan 2Influenza Vaccines 2Immunoenzyme Techniques 2Flow Cytometry 2Epoetin Alfa 2Data Collection 2Dabigatran 2Biopsy 2ziprasidone 1ribociclib 1ravulizumab 1palbociclib 1oprelvekin 1iron isomaltoside 1000 1fludarabine phosphate 1edoxaban 1calcium heparin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × ravulizumab × Classical hematology × Clear all
NCT06312644 2026-04-16

Study of UltomirisĀ® (Ravulizumab) Safety in Pregnancy

Alexion Pharmaceuticals, Inc.

Recruiting
75 enrolled
Classical hematology

Hemoglobinuria, Paroxysmal, Myasthenia Gravis, Neuromyelitis Optica, Atypical Hemolytic Uremic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon ⚔